Results from a collaboration between the Rabbitts Group (MRC Weatherall Institute of Molecular Medicine, WIMM) and the Russell group (Departments of Chemistry and Pharmacology) have recently been published in Nature Communications. The paper entitled ‘Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment’ describes a new approach using intracellular antibody fragments to block Protein-Protein Interactions (PPIs), use the fragments for target validation in disease models, and develop new small molecules against the PPI epitope. The work by the Rabbitt and Russell Groups used the approach to identify RAS-binding compounds with the aim of developing potential treatments for RAS-dependent cancers.
Find the full paper here https://www.nature.com/articles/s41467-018-05707-2